Active substance: ALECTINIBI
Mode of action:
The drug is an ALK blocker that works by blocking the action of ALK and thus slowing down the growth and spread of the cancer. ALK belongs to the receptor tyrosine kinase proteins that are involved in the growth of cells and the development of new blood vessels that bring them into the blood.
Treatment of non-small cell lung cancer when the cancer is ALK-positive, ie has a genetic defect in anaplastic lymphoma kinase, and has previously been treated with another anticancer medicine.
The medicine is taken with a meal. The capsules should be swallowed whole and not opened or dissolved.
If you miss a dose, it should be taken if it is more than six hours before your next dose. Do not take two doses at the same time. If the patient vomits after taking the medicine, the next dose will be taken at the usual time.
White hard capsule, 19.2 mm long, imprinted with ˮALEˮ in black on the cap and “150 mg” in black on the body.